I'rom Group Co., Ltd.

2372

JP3105170009

Healthcare Facilities & Services

Delayed Japan Exchange Other stock markets 02:00:00 2024-05-14 am EDT			5-day change	1st Jan Change
2,273 ^JPY	+21.36%		+23.87%	+13.14%

2023	I'rom Group Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	CI
2022	Lupin Ties Up with I'rom Group to Commercialize Denosumab in Japan	MT

I'rom Plans To Acquire DSU

March 31, 2017 at 12:00 am EDT

I'rom Group Co., Ltd. (TSE:2372) is planning to fully acquire DSU Pty Ltd. after June 2017.

Latest news about I'rom Group Co., Ltd.

I'rom Group Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-11	CI
Lupin Ties Up with I'rom Group to Commercialize Denosumab in Japan	22-08-25	MT
Lupin and I'rom Enter into an Exclusive Licensing Agreement for Denosumab Biosimilar for Japan	22-08-25	CI
Cogsmart Co., Ltd. announced that it has received ¥350 million in funding from Omron Ventures Co., Ltd., I'rom Group Co., Ltd., DG Daiwa Ventures Inc., IT-Farm Corporation, Makoto Capital Co., Ltd. and other investors	22-01-05	CI
I'rom Group Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2021, Payable June 29, 2021 and Provided Dividend Guidance for the Second Quarter and Fiscal Year 2022	21-05-10	CI
I'rom Group Co., Ltd. Reports Consolidated Earnings Results for the Nine Months Ended December 2019; Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 2020; Provides Year End Dividend for the Year Ending March 31, 2020	20-02-05	CI
Tranche Update on I'rom Group Co., Ltd.'s Equity Buyback Plan announced on February 26, 2019.	19-03-06	CI
I'rom Group Co., Ltd.'s Equity Buyback announced on February 26, 2019 has expired with 124,300 shares for ¥199.89 million.	19-03-04	CI
I'rom Group Co., Ltd. announces an Equity Buyback for 130,000 shares, representing 1.12% for ¥200 million.	19-02-26	CI
I'rom Group Co., Ltd. authorizes a Buyback Plan.	19-02-25	CI
Tranche Update on I'rom Group Co., Ltd.'s Equity Buyback Plan announced on November 8, 2018.	18-11-29	CI
I'rom Group Co., Ltd.'s Equity Buyback announced on November 8, 2018 has expired with 89,800 shares for ¥199.86 million.	18-11-28	CI
I'rom Group Co., Ltd. announces an Equity Buyback for 110,000 shares, representing 0.94% for ¥200 million.	18-11-08	CI
I'rom Group Co., Ltd. authorizes a Buyback Plan.	18-11-07	CI
I'rom Group Co., Ltd.(TSE:2372) added to S&P Global BMI Index	18-09-24	CI
An undisclosed buyer cancelled the acquisition of I'rom OK Co., Ltd. from I'rom Group Co., Ltd..	18-05-25	CI
I'rom Group Co., Ltd. Reports Consolidated Earnings Results for the Nine Months Ended December 2017; Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 2018	18-02-07	CI
I'rom Group Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2017; Provides Earnings Guidance for the Fiscal Year Ending March 2018; Declares Dividend for the Second Quarter of Fiscal 2018, Payable on December 15, 2017	17-11-08	CI
OKEIOS Co., Ltd. announced that it has received funding from I'rom Group Co., Ltd.	17-10-16	CI
I'rom Group Co., Ltd. completed the acquisition CMAX Clinical Research Pty Ltd from IDT Australia Limited for AUD 16.2 million.	17-08-22	CI
I'rom Group Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2017; Provides Earnings Guidance for the Year Ending March 31, 2018	17-08-08	CI
An undisclosed buyer signed a contract to acquire I'rom OK Co., Ltd. from I'rom Group Co., Ltd. for ¥810 million.	17-05-25	CI
I'rom Group Co., Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Full Year Ended March 31, 2017; Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2018	17-05-11	CI
I'rom Plans To Acquire DSU	17-03-31	CI
I'rom Group Co., Ltd. entered into contract to acquire Ethic Co., Ltd. from Yasutomo Yamauchi, Shitotomo Yamauchi, and other sellers for ¥96.8 million.	17-03-30	CI

I'rom Group Co.,Ltd. is engaged in medical fields such as regenerative medicine and gene discovery. The Company operates through four business segments. The SMO segment provides support services for contracting or substituting a part of the work related to conducting clinical trials from the conducting medical institution. The CRO segment provides all or part of clinical trial operations from pharmaceutical companies and others. The Advanced Medicinal Treatment segment is engaged in the development of gene therapy products, the development, manufacture and sale of products in the field of regenerative medicine based on iPS cells related technologies, as well as the provision of contract manufacture services. The Medical Support segment provides general and comprehensive support for medical business management, such as setting up and renting clinic malls, selling products and related services. The Company also provides business utilizing IT infrastructure.

Sector

Healthcare Facilities & Services

Calendar

2024-07-31 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
I'ROM GROUP CO., LTD.	+13.14%	145M
SONIC HEALTHCARE LIMITED	-13.90%	8.58B
RADNET, INC.	+60.25%	4.12B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-43.01%	2.29B
SYNLAB AG	-9.98%	2.44B
DR. LAL PATHLABS LIMITED	-3.02%	2.48B
NEOGENOMICS, INC.	-3.40%	2B
FLEURY S.A.	-19.79%	1.53B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.57%	1.21B
METROPOLIS HEALTHCARE LIMITED	+9.11%	1.12B

Medical & Diagnostic Laboratories

I'rom Group Co., Ltd.

Equities

2372

JP3105170009

Healthcare Facilities & Services

I'rom Plans To Acquire DSU

Latest news about I'rom Group Co., Ltd.

Chart I'rom Group Co., Ltd.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Medical & Diagnostic Laboratories